Experience with rufinamide in a pediatric population: a single center's experience.
Publication/Presentation Date
9-1-2010
Abstract
Rufinamide is a new antiepileptic drug recently approved as adjunctive treatment for generalized seizures in Lennox-Gastaut syndrome. We undertook a retrospective analysis of 77 patients with refractory epilepsy and receiving rufinamide to evaluate the drug's efficacy, tolerability, safety, and dosing schedules. It appeared efficacious in diverse epilepsy syndromes, with the highest responder rate in focal cryptogenic epilepsies (81.1% of patients with >50% response rate), and in diverse seizure types, with the highest responder rate in tonic/atonic and partial seizures (48.6% and 46.7% of patients with >50% response rate, respectively). Rufinamide was well tolerated: only 13% of patients developed side effects necessitating drug withdrawal. These findings suggest that rufinamide may possess good efficacy and tolerability, and that its efficacy may extend to epilepsy syndromes beyond Lennox-Gastaut, including both partial and generalized epilepsy syndromes.
Volume
43
Issue
3
First Page
155
Last Page
158
ISSN
1873-5150
Published In/Presented At
Vendrame, M., Loddenkemper, T., Gooty, V. D., Takeoka, M., Rotenberg, A., Bergin, A. M., Eksioglu, Y. Z., Poduri, A., Duffy, F. H., Libenson, M., Bourgeois, B. F., & Kothare, S. V. (2010). Experience with rufinamide in a pediatric population: a single center's experience. Pediatric neurology, 43(3), 155–158. https://doi.org/10.1016/j.pediatrneurol.2010.04.003
Disciplines
Medicine and Health Sciences
PubMedID
20691934
Department(s)
Department of Medicine
Document Type
Article